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Why was the cohort set up?
East London Genes & Health (ELGH) is a community
based, long-term study of health and disease in British
Bangladeshi and British Pakistani people in east London.
ELGH has a population-based design incorporating cutting
edge genomics with electronic health record (EHR) data
linkage and targeted recall-by-genotype (RbG) studies.
ELGH currently has 38 899 volunteers and is actively
recruiting with funding to expand to 100 000 volunteers
by 2023. ELGH is an open access data resource, and its re-
search will impact upon a population at high need and will
redress the poor representation of non-White ethnic groups
in existing population genomic cohorts.1
Almost a quarter of the world’s population, and 5% of
the UK population, are of South Asian origin.2 The risk of
coronary heart disease is three to four times higher, and of
type 2 diabetes (T2D) two to four times higher, in British
South Asians compared with White British people.3,4 East
London incorporates one of the UK’s largest South Asian
communities (29% of 1.95 million people), of which 70%
are British Bangladeshi and British Pakistani, and its popu-
lation live in high levels of deprivation (Tower Hamlets,
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Hackney, Barking and Dagenham are the 9th, 10th and
11th most deprived local authorities in England).5
Compared with White British people, British South Asians
living in east London have a 2-fold greater risk of develop-
ing T2D,6 nearly double the risk of non-alcoholic liver dis-
ease7(many volunteers are practising Muslims and do not
drink alcohol) and over double the risk of multimorbidity,8
with the onset of cardiovascular disease occurring 8 years
earlier in men.8 Determinants of poor cardiometabolic
health start early in the life course, and east London rates
of overweight and obese children are among the highest in
the UK.
Recent genomic advances offer exciting potential to bet-
ter understand the genetic causation of disease,9 including
rare loss-of-function gene variants.10 Genetic variation rele-
vant to British Bangladeshi and British Pakistani popula-
tions, such as autozygosity arising from parental relatedness,
is under-researched with regards to potential effects on com-
plex adult phenotypes at a population level.11,12
ELGH fosters authentic, inclusive, long-term engage-
ment in its research, to deliver future health benefits to the
population it represents. Community involvement in
ELGH helps prioritize areas for research, including T2D,
cardiovascular disease, dementia and mental health.
ELGH undertakes a range of public engagement work, in-
cluding collaboration with the award-winning Centre of
the Cell.13
Who is in the cohort?
ELGH (see Figure 1) incorporates population-wide recruit-
ment to Stage 1 studies, and targeted recruitment to Stage
2 recall-by-genotype (RbG) studies. Stage 3 and 4 studies
are planned.
During Stage 1, ELGH invites voluntary participation
of all British Bangladeshi and British Pakistani individuals
aged 16 and over, living in, working in or within reach of
east London. Recruitment is largely undertaken by bilin-
gual health researchers, and takes place in: (i) community
settings, e.g. mosques, markets and libraries, supported by
a third-sector partner organization (Social Action for
Health); and (ii) health care settings, e.g. GP surgeries, out-
patient clinics. Stage 1 volunteers complete a brief ques-
tionnaire, give consent to lifelong EHR linkage and donate
a saliva sample for DNA extraction and genetic tests.
Between April 2015 and mid-June 2019, ELGH recruited
38 899 volunteers to Stage 1. At the most recent data link-
age (November 2018), 97% of 31 646 had valid NHS
numbers: 61% had linked primary care health record data
available; 84% had linked secondary care data. By 2020,
near-complete (>95%) linkage to primary care health
records is expected with improved data connectivity, sup-
ported by Health Data Research UK. Recruitment into
outer London regions, and a new study site in Bradford,
are planned for 2019/20, areas with similar ethnic popula-
tions and comparable health needs.
Figure 1. ELGH study design. Stage 1 and 2 studies have commenced. Stage 3 and 4 studies will commence in 2019.
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Summary data from the Stage 1 volunteer questionnaire
and EHR data linkage are presented in Table 1, including
both baseline and longitudinal health data. Basic demo-
graphics of ELGH volunteers are compared with
population-wide data in Figure 2, and highlight that the
convenience sampling approach in Stage 1 recruitment has
achieved a sample broadly representative of the back-
ground population with regard to age and sex, but which
modestly favours recruitment of women over men in those
aged <45 years. ELGH volunteers live in areas of high dep-
rivation (97% in the most deprived two quintiles of the
Index of Multiple Deprivation). Parental relatedness is
reported by 19% of ELGH volunteers.
ELGH operates under ethical approval, 14/LO/1240,
from London South East NRES Committee of the Health
Research Authority, dated 16 September 2014.
How often have they been followed up?
ELGH contains real-world EHR data, its collection trig-
gered by a broad range of clinical encounters including
routine and emergency care. East London has an extensive
track record of using routine clinical health care data (pre-
dominantly from primary care) in research studies.6,7,14
Electronic performance dashboards are embedded in clini-
cal practice, facilitating high quality and equitable disease
screening and clinical care.15,16 Primary care health
records were digitized around 2000 and offer a rich source
of data on clinical encounters since then, but also include
pre-digitization dates of diagnoses and summarized clinical
events (e.g. type 2 diabetes, diagnosed in 1992). Health
data linkage and extraction takes place 3-monthly and
ELGH volunteers have consented for lifelong EHR access,
facilitating longitudinal follow-up.
ELGH can invite volunteers to Stage 2 studies up to
four times per year for more detailed study visits, e.g. recall
by genotype (RbG) and/or phenotype, for clinical assess-
ment and collection of biological samples, subject to ethics
approval, volunteer acceptability and community advisory
group approval. As at August 2019, around 60 ELGH vol-
unteers have participated in Stage 2 RbG studies.
What has been measured?
Available data are summarized in Table 2.
• Volunteer questionnaire (Supplementary File 1, available
as Supplementary data at IJE online). This self-report
questionnaire collects brief data including: name, date of
birth, sex, ethnicity, contact details, diabetes status, pa-
rental relatedness and overall assessment of general
health and well-being. The questionnaire has been
designed to facilitate high throughput recruitment and
volunteer inclusivity where language and cultural differ-
ences may exist, and to be used with or without re-
searcher assistance. The questionnaire does not capture
environmental factors (e.g. no self-reported data on
smoking, alcohol, diet, physical activity—although
smoking and alcohol use are available from other data
sources, discussed below). Completion of the volunteer
Table 1. Baseline characteristics of ELGH volunteers from
self-reported questionnaire and electronic health record data
Self-reported questionnaire data (n 5 31 646)
Year of birth n ¼ 31 634 Median 1977
Interquartile range 1967-85;
range 1915-2002
Sex n ¼ 31 639 Male n ¼ 13 928 (44%)
Female n ¼ 17 710 (56%)
Ethnicity n ¼ 31 508 Bangladeshi or British
Bangladeshi n ¼ 21 083
(67%)
Pakistani or British Pakistani
n ¼ 10 319 (33%)
Parental relatedness Yes ¼ 5959 (18.8%)
No ¼ 24 601 (77.8%)
Don’t know ¼ 1013 (3.2%)
Not documented ¼ 77 (0.2%)
Linked electronic health record data (n 5 21 514)
Index of Multiple Deprivation
(2015)
Quintile 1 (most deprived),
n ¼ 12 551 (58%)
Quintile 2, n ¼ 8400 (39%)
Quintile 3, n ¼ 411 (2%)
Quintile 4, n ¼ 131 (0.6%)
Quintile 5 (least deprived),
n ¼ 11 (0%)
Number of ELGH volunteers with common conditions:
Type 2 diabetes 4769 (22%)
Hypertension 3956 (18%)
Ischaemic heart disease 1048 (4.9%)
Dementia 47 (0.2%)
Asthma 2297 (10.7%)
COPD 255 (1.2%)
Number of ELGH volunteers with commonly recorded clinical data
measured in the past 5 years:
Body mass index 18 654 (86.7%)
Mean ¼ 27.16kg/m2
Standard deviation ¼
4.87kg/m2
Range ¼ 14–69kg/m2
Smoking status 18 938 (88%)
Never smoked ¼ 14 353 (76%)
Ex-smoker ¼ 2146 (11%)
Current smoker ¼ 2276 (12%)
Uninformative coding ¼
194 (1%)
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questionnaire triggers health record data linkage via
NHS number.
• NHS primary care health record data linkage. We first de-
sign data extraction in human-readable form (Supplementary
File 2, available as Supplementary data at IJE online) and
then code this in Structured Query Language
(Supplementary File 4, available as Supplementary data at
IJE online). Coded fields are extracted from EHR systems,
curated to research phenotypes of interest and developed
both incrementally and on demand. Search terms are used,
including READ2 diagnostic codes, prescribing data, labora-
tory test results and clinical measurements and processes.
Data concordance was checked between volunteer ques-
tionnaires and their EHR, with >99% concordance for
gender and year of birth. Almost all cases of data discor-
dance were due to technical errors with questionnaire opti-
cal character recognition or user data completion, and
were resolved with manual checking. Data outside clini-
cally plausible ranges, or with clear data entry errors, are
removed. A detailed description of our data processing is
in Supplementary File 3, available as Supplementary data
at IJE online. Missing data exist, but at relatively low fre-
quency in routinely collected and incentivized clinical
measures, e.g. smoking status is recorded in the EHR of
88% of volunteers in the 5 years preceding the most recent
data linkage. Repeated measures of routinely collected
data and cross-validation across information sources can
mitigate the impact of missing data where it exists, as can
statistical techniques, such as sensitivity analysis and multi-
ple imputation.17
• NHS local secondary care health record data linkage.
Linkage to Barts Health NHS Trust data provides
secondary care data for all ELGH volunteers who have
attended this hospital system (24 852 volunteers at the
latest linkage). Available data include clinician-coded
SNOMED-CT acute and chronic problem lists, labora-
tory and imaging results. OPCS-4 (Office for Population,
Censuses and Surveys) and ICD-10 (World Health
Organization International Classification of Diseases and
Related Health Problems) codes are available for every
finished episode of care. For example, maternity data
linkage within Barts Health identified 4172 female
ELGH volunteers with maternity records available for
one or more pregnancies. Linkage to other local hospitals
(including those providing mental and community health
care) is planned in 2019/2020.
• Planned linkage to national health record and other data-
sets. ELGH will link to further datasets in 2019/2020, in-
cluding national NHS Hospital Episode Statistics (HES)
and NHS Mortality Data,18,19 to include admissions and
discharge, diagnosis and operation codes, maternity, psy-
chiatric and critical care from 1997, and accident and
emergency data, ICD-10 and OPCS-4 codes from 2008.
NHS mortality data provide data on cause of death.
Other planned data linkages to national registries include
the National Cancer Registration and Analysis Service
and National Cardiovascular Outcomes Research.
• Genomics. DNA is extracted from the Oragene (DNA
Genotek) saliva system and stored from all Stage 1 vol-
unteers. To date, 20-40X depth exome sequencing has
been performed (n ¼ 3781) or is in progress (n ¼ 1492)
on volunteers reporting parental relatedness.
By late 2019 (funding secured), 50 000 samples from
stage 1 volunteers will be genotyped on the Illumina
Infinium Global Screening Array v3.0 (with an additional
Figure 2. Population pyramid showing age and sex of ELGH volunteers (n¼ 29 370) versus the total population of British Bangladeshi and British
Pakistani people (n¼ 152 564) in east London (all NHS GP-registered adults residing in the London Boroughs of City and Hackney, Newham, Tower
Hamlets, Waltham Forest), aged  16 years.
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46 662 Multi-Disease variants).20 Array content includes
rare disease-associated mutations (e.g. all pathogenic and
likely pathogenic variants in ClinVar), pharmacogenetic
associations and genome-wide coverage for association
studies (based on the 26 populations present in Phase III of
1000 Genomes Project, optimized for imputation
accuracy), polygenic risk score and Mendelian random-
ization studies.
In 2019/2020, if support is secured from an evolving
Life Sciences Industry Consortium or elsewhere, high-
depth exome sequencing will be performed on up to
50 000 volunteer samples. The intention is for genotyping
Table 2. Summary of all data types currently available in ELGH for Stage 1 volunteers, and planned for late 2019 onwards
Data source Data fields Volunteers Duration of data collection
Volunteer questionnaire Basic details: name, date of birth, ethnicity, ad-
dress, GP, NHS number
All Cross-sectional at study
entry
Self-reported diabetes status
Self-reported parental relatedness
Self-assessment of overall health and well-being
Electronic health records Primary care (GP) records (currently coded in
READ2 or CTV3 clinical terminologies):
All volunteers where data
linkage is possible (currently
61%, due to increase to
>95% in 2019 with linkage
to a wider GP practice
network)
Real-world data with access
to all available historical
(retrospective) data and
lifelong (prospective)
data
Sociodemographic data
Diagnoses
Prescribing data
Clinical measurements, e.g. height, weight, body
mass index, blood pressure
Laboratory tests (e.g. blood tests)
Care processes, e.g. referrals
Quality and Outcomes Framework indicators:
including care processes and outcomes for
common diseases (e.g. diabetes, asthma, de-
pression), public health concerns (smoking,
obesity) and preventative measures (e.g. blood
pressure checks)
NHS Health Checks: screening for diabetes,
heart disease, kidney disease, stroke and de-
mentia offered to 40–74 year olds
Secondary care (hospital) records: All volunteers in contact with
secondary (hospital) care
Real-world data, includes
retrospective data since
2012 and lifelong (pro-
spective) data
Diagnoses (ICD10) and procedures (OPCS-4)
Chronic problem listing (SNOMED)
Laboratory tests (e.g. blood tests, histopathol-
ogy, microbiology)
Maternity records
External health record data
sets and registries
Hospital Episode Statistics All volunteers (planned) Real-world data, includes
retrospective data since
2003, and lifelong (pro-
spective) data
Office for National Statistics mortality data
National Cancer Registration and Analysis
Service, NCRAS
National Cardiovascular Outcomes Research:
national audits
Genetic investigations Whole exome sequencing All volunteers reporting paren-
tal relatedness (currently
19%)
Not applicable
Illumina Infinium Global Screening Array
v3.0þMD
All volunteers up to 50 000 (to
be undertaken in early 2019)
Not applicable
Recall studies Bespoke clinical phenotyping and sample collec-
tion according to genotype of interest. Core
samples taken on all for methylation assays,
transcriptomics, lipidomics and metabolomics
60 volunteers to date, with ap-
proval for all volunteers to
be approached for recall up
to four times per year
Dependent on protocol
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and high-depth exome sequencing to be performed on up
to 100 000 volunteer samples by 2023.
• Samples for other –omics. Core study samples are taken
from all volunteers recalled in stage 2 studies, including
a blood cell pellet (for repeat DNA analyses), plasma
aliquots and blood cell RNA preservation (Paxgene), for
studies including methylation assays, transcriptomics,
proteomics, lipidomics and metabolomics.
What has it found: key findings and
publications?
ELGH is a new resource that continues to grow in size and
content and, to date, has been used for three main areas of
work, as follows.
Characterization of common phenotypes
Using Type 2 diabetes (T2D) as an exemplar, we show the
ability for detailed phenotypic characterization of ELGH
volunteers using EHRs (Table 3). Of 21 514 volunteers in
ELGH with available linked EHR data, 4769 (22%) have
a diagnosis of T2D in their primary care record. Basic soci-
odemographic data (age, gender, ethnicity) of volunteers
were recorded in 100%, and smoking status had been
obtained within 2 years of the most recent data linkage in
94%. In over 97% of volunteers with T2D, body mass in-
dex, markers of glucose control (HbA1c) and serum cho-
lesterol were measured and available in the 2 years
preceding ELGH participation. Hypertension, ischaemic
heart disease and chronic kidney disease were observed in
47%, 15% and 11%, respectively, of the 4769, and erectile
dysfunction was present in 26% of men. Retinal complica-
tions of T2D are recorded and graded, with 82% of volun-
teers having undergone screening within the past 2 years.
Prescribing data show recent insulin prescriptions in 16%,
and the use of single or multiple non-insulin agents, as well
as use of cardiovascular drugs (e.g. lipid-lowering therapy).
These data show the potential to perform cross-sectional
analyses in ELGH from EHR data.
EHR data also give the potential to study longitudinal
phenotypic traits, retrospectively and prospectively.
Median duration of T2D in ELGH volunteers was 7 years
(range 0–51 years). For all volunteers with T2D, year of
onset was recorded, and prescribing data and clinical
measurements (including body mass index, HbA1c and
cholesterol) at the time of diagnosis (þ/- 6 months) were
available for nearly two-thirds of volunteers. Before T2D
onset, 26% (993) had had a diagnosis of pre-diabetes and
16% (370) of women had had a diagnosis of gestational
diabetes, allowing study of progression from at-risk to dis-
ease states.
Multimorbidity is an increasing problem in ageing pop-
ulations with high rates of chronic long-term disease; in
the ELGH population we identified that of the 4769
ELGH volunteers with T2D, 80% had at least one, and
27% had two or more cardiovascular multimorbidities
(Table 3).
Rare allele frequency gene variants occurring as
homozygotes, including predicted loss-of-function
knockouts
All ELGH volunteers self-reporting parental relatedness
(19%) have been selected for exome sequencing. Genomic
autozygosity (homozygous regions of the genome identical
by descent from a recent common ancestor) means that
rare allele frequency (minor allele frequency <0.5%) var-
iants normally only seen as heterozygotes are enriched for
homozygote genotypes. ELGH expands existing, smaller
studies of autozygosity to investigate the health and popu-
lation effects of such variants, with a focus on loss of func-
tion variants.11,21,22 The accuracy of self-reported parental
relatedness to actual autozygosity measured at the DNA
level by exome sequencing (Figure 3) is a modest predictor
of actual autozygosity, e.g. we find 8.2% of individuals
who declare that their parents are not related in fact have
>2.5% genomic autozygosity. For British Bangladeshi vol-
unteers, mean autozygosity is slightly lower than expected
given the reported parental relationship (possibly due to
confusion over the meaning of e.g. ‘first cousin’ versus
‘second cousin’), whereas for British Pakistani volunteers,
mean autozygosity is slightly higher than expected (possi-
bly due to historical parental relatedness). With an ELGH
sample size of 100 000 we estimate we will identify rare
variant-predicted loss-of-function homozygotes in >5000
human genes. ELGH plans to work with other studies on
an international human knockout variant browser.
Recall by genotype (and/or phenotype) studies
RbG studies, applied to population cohorts with genomic
data, are of increasing research interest23 and use the ran-
dom allocation of alleles at conception (Mendelian
randomization) to aid causal inference in population stud-
ies, reduce biases seen with observational studies and de-
velop functional studies. RbG studies can target specific
single variants (or an allelic series for a gene) and polygenic
variants (e.g. extremes of polygenic risk scores).
ELGH is undertaking RbG studies in Stage 2 using be-
spoke clinical phenotyping tailored to the genotype or phe-
notype of interest. To date, three research consortia have
6 International Journal of Epidemiology, 2019, Vol. 0, No. 0
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyz174/5555939 by guest on 02 April 2020
Table 3. Example of a specific disease phenotype: characteristics of ELGH volunteers with type 2 diabetes. Data are presented in
summary and descriptive formats as indicated. Missing data are estimated where available, e.g. for clinical care processes and
measurements, but not diagnostic coding where the absence of a code is taken to indicate the absence of a diagnosis
Volunteers with type 2 diabetes ¼ 4769 (22%) Missing
data
Sociodemographic data Age Mean years (sd) 46 (11) 0%
Sex Male, n (%) 2445 (51)
Female, n (%) 2324 (49)
Ethnicity British Bangladeshi and Bangladeshi, n (%) 3860 (81)
British Pakistani and Pakistani, n (%) 822 (17)
Other, n (%) 87 (2)
Index of Multiple
Deprivation (2015)
Quintile 1 (most deprived), n (%) 12551 (58) 0%
Quintile 2, n (%) 8400 (39)
Quintile 3, n (%) 411 (2)
Quintile 4, n (%) 131 (1)
Quintile 5 (least deprived), n (%) 11 (0)
Smoking status (recorded in
the past 2 years)
Data available, n 4712 6%
Never smoked, n (%) 3348 (71)
Ex-smoker, n (%) 810 (17)
Current smoker, n (%) 554 (12)
Coding uninformative, n (%) 57 (1)
Country of birth Data available, n 2585 46%
Born in Bangladesh, n (%) 2130 (82)
Born in Pakistan, n (%) 347 (13)
Born in England, n (%) 54 (2)
Born elsewhere, n (%) 54 (2)
Historic T2D data Age at T2D onset Data available, n 4769 0%
Mean years (sd) 46 (11)
Duration of T2D Data available, n 4769
Years (range) 7 (0–51)
Diabetes risk state before
T2D
Pre-diabetes, n (%) 1241 (26) NA
Gestational diabetes (females), n (%) 370 (16)
Body mass index (BMI) at
T2D diagnosis
Data available, n 3507 5%
Mean kg/m2 (sd) 28.8 (4.9)
HbA1c at T2D diagnosis Data available, n 3176 33%
Mean HbA1c mmol/mol (sd) 61.9 (18.7)
Total cholesterol at T2D
diagnosis
Data available, n 3427 28%
Mean total cholesterol, mmol/l 5.0 (1.2)
Current T2D data (recorded
within the past 2 years)
Body mass index Data available, n 4630 3%
Mean kg/m2 (sd) 27.9 (4.8)
HbA1c Data available, n 4656 2%
Mean mmol/mol (sd) 59.2 (15.6)
Total cholesterol Data available, n 4640 3%
Mean total cholesterol, mmol/l 3.8 (1.0)
Retinal screening Data available 4769 NA
Not in the screening programme, n (%) 241 (5)
In the screening programme, n (%) 4528 (95)
Screened in past 2 years, n (%) 3926 (82)
Diabetes complications and
multimorbidity
Other diagnoses Hypertension, n (%) 2245 (47) NA
Chronic kidney disease, n (%) 516 (11)
Neuropathy, n (%) 164 (3)
Ischaemic heart disease, n (%) 719 (15)
Peripheral vascular disease, n (%) 174 (4)
Erectile dysfunction (males), n (%) 1310 (27)
Stroke, n (%) 180 (4)
Atrial fibrillation, n (%) 54 (1)
Heart failure, n (%) 126 (3)
(continued)
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undertaken ELGH RbG studies, one recalling volunteers
with loss-of-function gene variants relevant to immune
phenotypes, another phenotyping individuals with rare
variants in genes implicated in T2D and obesity and a third
involving an industrial partnership to aid therapeutic de-
velopment for a rare autosomal recessive metabolic disor-
der.24 Successful recall completion rates to these RbG
studies are between 30% and 40%.
What are the main strengths and
weaknesses?
ELGH has multiple strengths as a large, population-based
study, and its novel, pragmatic design offers opportunities
to combine genomic investigation with longitudinal and
cross-sectional description of health and disease as deter-
mined from EHR data.25 ELGH reaches a British
Bangladeshi and British Pakistani population with a high
Table 3. Continued
Volunteers with type 2 diabetes ¼ 4769 (22%) Missing
data
Number of cardiovascular
multimorbidities in the
presence of type 2
diabetes
One or more conditions, n (%) 3804 (80)
Two or more conditions, n (%) 1291 (27)
Three or more conditions, n (%) 468 (10)
Four or moreconditions, n (%) 198 (4)
Five or more conditions, n (%) 85 (2)
Drug prescribing Insulin Prescribed in the past 12 months, n (%) 756 (16) NA
Mean years on insulin, (sd) 8.8 (5)
Non-insulin diabetes
therapies
Metformin prescribed in the past 12 months,
n (%)
3695 (77)
Sulphonylurea prescribed in past 12 months,
n (%)
1321 (28)
Prescribing regimens Prescribed no non-insulin diabetes therapies,
n (%)
845 (18)
Prescribed one non-insulin diabetes therapy,
n (%)
2057 (43)
Prescribed two non-insulin diabetes thera-
pies, n (%)
1127 (24)
Prescribed three or more non-insulin diabetes
therapies, n (%)
740 (16)
Lipid-lowering treatment Prescribed in the past 12 months, n (%) 4256 (89)
NA, not available; sd, standard deviation.
Figure 3. Distribution of levels of autozygosity as a fraction of the genome in ELGH volunteers, split according to self-reported parental relatedness
and ethnicity (Tukey box plot showing median, lower and upper quartiles, quartiles þ/- 1.5x interquartile range, and outliers).
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burden of disease, generalizable to a wider global pop-
ulation and building on existing genetic studies that have
been criticized for focusing on White populations and sub-
stantially under-recruiting from minority ethnic groups.26
High rates of autozygosity in ELGH volunteers lead to ho-
mozygous genotypes at variants with rare allele frequencies
that will aid gene discovery, and RbG studies will generate
novel translational impact.11,24 Future studies on auto-
zygosity will inform novel population level insights into
the impact of genetic variation on health. The ability to in-
vite all volunteers to Stage 2 studies offers the possibility to
develop subcohorts and trials within cohorts in the future.
Our community-based recruitment approach offers
broad reach into the target population. However, to date,
ELGH has modestly over-recruited British Bangladeshi
versus British Pakistani volunteers. To support increased
recruitment of British Pakistani volunteers, recruitment is
expanding into outer London boroughs and a new
Bradford Genes & Health.
The use of real-world EHR data is both a strength and
weakness of ELGH. Strengths include the ability to obtain
longitudinal data available on multiple diseases and disease
risks via primary care, in large numbers of volunteers in a
feasible and cost-effective manner. Data linkage is not yet
complete, but will improve in 2019 with improved infra-
structure and linkage to national registries and databases.
Weaknesses are that EHR data may be inferior to observa-
tional epidemiological studies in ascertaining some pheno-
types, e.g. recent diseases of minor severity (which do not
necessarily require health care access) or subclinical dis-
ease. Additionally, although outcomes can be studied rela-
tively well, EHR data have limited opportunity to study
certain exposures, e.g. health behaviours, physical activity,
diet and some other environmental influences.
Can I get hold of the data? Where can I find
out more?
ELGH offers an open access resource to international, aca-
demic and industrial researchers to drive high-impact,
world-class science. Data access is managed at several lev-
els, as follows.
• Level 1. Fully open data: summary data are distributed
via our website, e.g. genotype counts and annotation of
knockout variants from exome sequencing, and preva-
lence of phenotype and traits data.
• Level 2. Genotype data (SNP chip genotyping, or high-
throughput sequencing) are (or will be) available under
data access agreements granted by the independent
Wellcome Sanger Institute Data Access Committee.
Individual sequencing (e.g. cram) and genotype files (e.g.
vcf) are available within 6 months on the European
Genome-phenome Archive27 (EGA).
• Level 3. Individual-level phenotype data are held in an
ISO27001 compliant data safe haven environment under
data access agreement, currently hosted by the UK Secure e-
Research Platform.28,29 The data safe haven contains the lat-
est genetic data linked to the questionnaire and health record
phenotypes, and data export is tightly controlled. This ‘bring
researchers to the data’ model allows us to share regular
data updates, maintain complex data linkages and avoid
large file data transfers. This model provides robust reassur-
ance to volunteers that their health data will be carefully
looked after, with maximum security against data breaches.
External researchers can to apply to undertake research
with ELGH via a formal application process(details are
available on the website), and most will be required to
have their own research ethics approval to work with
ELGH. Applications are assessed by both the executive
board and community advisory group, according to com-
munity prioritization, acceptability and scientific merit.
Cohort profile in a nutshell
• East London Genes & Health (ELGH) is a large-scale,
community genomics and health study (to date
38 899 volunteers; target 100 000 volunteers).
• ELGH was set up in 2015 to gain deeper understand-
ing of health and disease, and underlying genetic
influences, in British Bangladeshi and British
Pakistani people living in east London.
• ELGH prioritizes studies in areas important to, and
identified by, the community it represents. Current
priorities include cardiometabolic diseases (high prev-
alence of early onset) and mental illness. However,
studies in any scientific area are possible, subject to
community advisory group and ethical approval.
• ELGH combines health data science [using linked UK
National Health Service (NHS) electronic health re-
cord data] with exome sequencing and SNP array
genotyping to elucidate the genetic influence on
health and disease, including the contribution from
high rates of parental relatedness to rare genetic
variation and homozygosity (autozygosity), in two
understudied ethnic groups. Linkage to longitudinal
health record data enables both retrospective and
prospective analyses.
• Through Stage 2 studies, ELGH offers researchers
the opportunity to undertake recall-by-genotype and/
or recall-by-phenotype studies on volunteers.
Subcohort studies, trials within cohort and other
study designs are possible.
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Supplementary Data
Supplementary data are available at IJE online.
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